<strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>23</strong>, <strong>No</strong>. 1, <strong>2009</strong> Recommended INN: List 61C 41 H 71 N 3 O 8NH 3 CHOCH 3 HO OH 3 C CH 3N HHOHOHOHCH 3H OCH 3NHHOH 3 Ctosedostatumtosedostattosédostattosedostatcyclopentyl (2S)-2-{(2R)-2-[(S)-hydroxy(hydroxycarbamoyl)methyl]-4-methylpentanamido}-2-phenylacetate(2S)-2-({(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoéthyl]-4-méthylpentanoyl}amino)-2-phénylacétate de cyclopentyle(2S)-2-{(2R)-2-[(S)-hidroxi(hidroxicarbamoil)metil]-4-metilpentanamido}-2-fenilacetato de ciclopentiloC 21 H 30 N 2 O 6H 3 CHONHOHCH 3HHNOH OHOOtroplasminogenum alfa #troplasminogen alfathrombin-activable plasminogen:endo-[(558a(559)-558h(365))-human coagulation factor XI-(363-370)-peptide]-des-(559-562)-[606(610)-lysine,6<strong>23</strong>(627)-lysine]humanplasminogen, glycoform αtroplasminogène alfa plasminogène activable par la thrombine :endo-[(558a(559)-558h(365))-facteur XI de coagulation humain-(363-370)-peptide]-dès-(559-562)-[606(610)-lysine,6<strong>23</strong>(627)-lysine]plasminogène humain, glycoforme αtroplasminógeno alfa plasminógeno activable por la trombina :endo-[(558a(559)-558h(365))-facteur XI de coagulación humano-(363-370)-péptido]-des-(559-562)-[606(610)-lisina,6<strong>23</strong>(627)-lisina]plasminógeno humano, glicoforma α79
Recommended INN: List 61 <strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>23</strong>, <strong>No</strong>. 1, <strong>2009</strong>C 3875 H 5917 N 1107 O 1190 S 58EPLDDYVNTQ GASLFSVTKK QLGAGSIEEC AAKCEEDEEF TCRAFQYHSK 50EQQCVIMAEN RKSSIIIRMR DVVLFEKKVY LSECKTGNGK NYRGTMSKTK 100NGITCQKWSS TSPHRPRFSP ATHPSEGLEE NYCRNPDNDP QGPWCYTTDP 150EKRYDYCDIL ECEEECMHCS GENYDGKISK TMSGLECQAW DSQSPHAHGY 200IPSKFPNKNL KKNYCRNPDR ELRPWCFTTD PNKRWELCDI PRCTTPPPSS 250GPTYQCLKGT GENYRGNVAV TVSGHTCQHW SAQTPHTHNR TPENFPCKNL 300DENYCRNPDG KRAPWCHTTN SQVRWEYCKI PSCDSSPVST EQLAPTAPPE 350LTPVVQDCYH GDGQSYRGTS STTTTGKKCQ SWSSMTPHRH QKTPENYPNA 400GLTMNYCRNP DADKGPWCFT TDPSVRWEYC NLKKCSGTEA SVVAPPPVVL 450LPDVETPSEE DCMFGNGKGY RGKRATTVTG TPCQDWAAQE PHRHSIFTPE 500TNPRAGLEKN YCRNPDGDVG GPWCYTTNPR KLYDYCDVPQ CAAPSFDCGK 550PQVEPKKCTT KIKPRIVGGC VAHPHSWPWQ VSLRTRFGMH FCGGTLISPE 600WVLTAAHCLK KSPRPSSYKV ILGAHQKVNL EPHVQEIEVS RLFLEPTRKD 650IALLKLSSPA VITDKVIPAC LPSPNYVVAD RTECFITGWG ETQGTFGAGL 700LKEAQLPVIE NKVCNRYEFL NGRVQSTELC AGHLAGGTDS CQGDSGGPLV 750CFEKDKYILQ GVTSWGLGCA RPNKPGVYVR VSRFVTWIEG VMRNN 795Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro30-54 34-42 84-162 105-145 133-157 166-243 169-297 187-226215-<strong>23</strong>8 256-333 277-316 305-328 358-435 379-418 407-430 462-541483-524 512-536 548-670 558-570 592-608 684-751 714-730 741-769Glycosylation sites / Sites de glycosylation / Posiciones de glicosilaciónSer-249 Asn-289 Thr-346ustekinumabum #ustekinumabustékinumabustekinumabimmunoglobulin G1, anti-[Homo sapiens interleukin 12B (IL12B, IL12p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxiclymphocyte maturation factor 2, CLMF2, CMLF p40)], Homo sapiensmonoclonal antibody, CNTO 1275; gamma1 heavy chain (1-449)[Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfide with kappalight chain (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":<strong>23</strong>1-<strong>23</strong>1")-bisdisulfide dimerimmunoglobulin G1, anti-[Homo sapiens interleukine 12B (IL12B,IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxiclymphocyte maturation factor 2, CLMF2, CMLF2 p40)], Homosapiens anticorps monoclonal, CNTO 1275; chaîne lourde gamma1(1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfure avecla chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":<strong>23</strong>1-<strong>23</strong>1")-bisdisulfureinmunoglobulina G1, anti-[Homo sapiens interleukina 12B (IL12B,IL12 p40, factor 2 estimulante de las células natural killer NKSF2,factor 2 citotóxico de la maduraciòn de linfocitos, CLMF2, CMLF2p40)], Homo sapiens anticuerpo monoclonal, CNTO 1275; cadenapesada gamma1 (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)],(222-214')-disulfuro con la cadena ligera kappa (1'-214') [Homosapiens V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01(108'-214')]; dímero (228-228":<strong>23</strong>1-<strong>23</strong>1")-bisdisulfuroC 6482 H 10004 N 1712 O 2016 S 46vadimezanumvadimezanvadimézanvadimezan2-(6,7-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acidacide (5,6-diméthyl-9-oxo-9H-xanthén-4-yl)acétiqueácido 2-(6,7-dimetil-9-oxo-9H-xanten-4-ilo)ácetico80
- Page 2 and 3:
WHO Drug Information Vol 23, No. 1,
- Page 4 and 5:
WHO Drug Information Vol 23, No. 1,
- Page 6 and 7:
WHO Drug Information Vol 23, No. 1,
- Page 8 and 9:
WHO Drug Information Vol 23, No. 1,
- Page 10 and 11:
WHO Drug Information Vol 23, No. 1,
- Page 12 and 13:
WHO Drug Information Vol 23, No. 1,
- Page 14 and 15:
WHO Drug Information Vol 23, No. 1,
- Page 16 and 17:
WHO Drug Information Vol 23, No. 1,
- Page 18 and 19:
WHO Drug Information Vol 23, No. 1,
- Page 20 and 21:
WHO Drug Information Vol 23, No. 1,
- Page 22 and 23:
WHO Drug Information Vol 23, No. 1,
- Page 24 and 25:
WHO Drug Information Vol 23, No. 1,
- Page 26 and 27:
WHO Drug Information Vol 23, No. 1,
- Page 28 and 29:
WHO Drug Information Vol 23, No. 1,
- Page 30 and 31: WHO Drug Information Vol 23, No. 1,
- Page 32 and 33: WHO Drug Information Vol 23, No. 1,
- Page 34 and 35: WHO Drug Information Vol 23, No. 1,
- Page 36 and 37: WHO Drug Information Vol 23, No. 1,
- Page 38 and 39: WHO Drug Information Vol 23, No. 1,
- Page 40 and 41: WHO Drug Information Vol 23, No. 1,
- Page 42 and 43: WHO Drug Information Vol 23, No. 1,
- Page 44 and 45: WHO Drug Information Vol 23, No. 1,
- Page 46 and 47: WHO Drug Information Vol 23, No. 1,
- Page 48 and 49: WHO Drug Information Vol 23, No. 1,
- Page 50 and 51: WHO Drug Information, Vol. 23, No.
- Page 52 and 53: WHO Drug Information, Vol. 23, No.
- Page 54 and 55: WHO Drug Information, Vol. 23, No.
- Page 56 and 57: WHO Drug Information, Vol. 23, No.
- Page 58 and 59: WHO Drug Information, Vol. 23, No.
- Page 60 and 61: WHO Drug Information, Vol. 23, No.
- Page 62 and 63: WHO Drug Information, Vol. 23, No.
- Page 64 and 65: WHO Drug Information, Vol. 23, No.
- Page 66 and 67: WHO Drug Information, Vol. 23, No.
- Page 68 and 69: WHO Drug Information, Vol. 23, No.
- Page 70 and 71: WHO Drug Information, Vol. 23, No.
- Page 72 and 73: WHO Drug Information, Vol. 23, No.
- Page 74 and 75: WHO Drug Information, Vol. 23, No.
- Page 76 and 77: WHO Drug Information, Vol. 23, No.
- Page 78 and 79: WHO Drug Information, Vol. 23, No.
- Page 82 and 83: WHO Drug Information, Vol. 23, No.
- Page 84: WHO Drug Information, Vol. 23, No.
Change language